Brodalumab for the treatment of refractory Sweet syndrome

International Journal of DermatologyEarly View Letter to the Editor Brodalumab for the treatment of refractory Sweet syndrome Po-Chien Wu, Po-Chien Wu orcid.org/0000-0002-2218-6083 Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, TaiwanSearch for more papers by this authorChun-Bing Chen, Chun-Bing Chen Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this authorWen-Hung Chung, Wen-Hung Chung Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this authorChing-Chi Chi, Corresponding Author Ching-Chi Chi [email protected] orcid.org/0000-0001-5699-0283 Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this author Po-Chien Wu, Po-Chien Wu orcid.org/0000-0002-2218-6083 Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, TaiwanSearch for more papers by this authorChun-Bing Chen, Chun-Bing Chen Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this authorWen-Hung Chung, Wen-Hung Chung Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this authorChing-Chi Chi, Corresponding Author Ching-Chi Chi [email protected] orcid.org/0000-0001-5699-0283 Department of Dermatology, Chang Gung Memorial Hospital, Taoyuan, Taiwan School of Medicine, College of Medicine, Chang Gung University, Taoyuan, TaiwanSearch for more papers by this author First published: 10 May 2024 https://doi.org/10.1111/ijd.17197 Conflict of interest: None. Funding source: None. Read the full textAboutPDF ToolsRequest permissionExport citationAdd to favoritesTrack citation ShareShare Give accessShare full text accessShare full-text accessPlease review our Terms and Conditions of Use and check box below to share full-text version of article.I have read and accept the Wiley Online Library Terms and Conditions of UseShareable LinkUse the link below to share a full-text version of this article with your friends and colleagues. Learn more.Copy URL Share a linkShare onEmailFacebookTwitterLinkedInRedditWechat No abstract is available for this article. References 1Heath MS, Ortega-Loayza AG. Insights into the pathogenesis of Sweet's syndrome. Front Immunol. 2019; 10: 414. 10.3389/fimmu.2019.00414 CASPubMedWeb of Science®Google Scholar 2Bonnekoh H, Erpenbeck L. Neutrophilic dermatoses – pathomechanistic concepts and therapeutic developments. J Dtsch Dermatol Ges. 2023; 21: 374–380. 10.1111/ddg.15055 Google Scholar 3Joshi TP, Friske SK, Hsiou DA, Duvic M. New practical aspects of sweet syndrome. Am J Clin Dermatol. 2022; 23: 301–318. 10.1007/s40257-022-00673-4 PubMedWeb of Science®Google Scholar 4Marzano AV, Cugno M, Trevisan V, Fanoni D, Venegoni L, Berti E, et al. Role of inflammatory cells, cytokines and matrix metalloproteinases in neutrophil-mediated skin diseases. Clin Exp Immunol. 2010; 162: 100–107. 10.1111/j.1365-2249.2010.04201.x CASPubMedWeb of Science®Google Scholar 5Calabrese L, Caldarola G, Peris K, De Simone C. Recalcitrant Sweet syndrome successfully treated with adalimumab. J Dtsch Dermatol Ges. 2021; 19: 122–124. 10.1111/ddg.14223 Web of Science®Google Scholar Early ViewOnline Version of Record before inclusion in an issue ReferencesRelatedInformation